These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28870589)

  • 1. Subcutaneous "bolus" immunoglobulin dose in CIDP: A proof-of concept study.
    Cocito D; Peci E; Romagnolo A; Rigaldo S; Rosso M; Lopiano L; Merola A
    J Neurol Sci; 2017 Sep; 380():54-57. PubMed ID: 28870589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
    Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
    Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
    van Schaik IN; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Praus M; Mielke O; Durn BL; Cornblath DR; Merkies ISJ;
    Lancet Neurol; 2018 Jan; 17(1):35-46. PubMed ID: 29122523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.
    Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J;
    Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy.
    Markvardsen LH; Harbo T; Sindrup SH; Christiansen I; Andersen H; Jakobsen J;
    Eur J Neurol; 2014 Dec; 21(12):1465-70. PubMed ID: 25041191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
    Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
    Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Tedeschi G
    Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical-neurophysiological correlations in chronic inflammatory demyelinating polyradiculoneuropathy patients treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Ricciardi D; Tedeschi G
    Muscle Nerve; 2019 Dec; 60(6):662-667. PubMed ID: 31415091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manual push technique, an alternative route of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyradiculoneuropathy: A proof-of-concept study.
    Cocito D; Peci E; Rigaldo S; Canavese C; Migliaretti G; Cossa FM
    Clin Neurol Neurosurg; 2020 Nov; 198():106240. PubMed ID: 32971302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
    Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
    Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An international multicenter efficacy and safety study of IqYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study.
    Nobile-Orazio E; Pujol S; Kasiborski F; Ouaja R; Corte GD; Bonek R; Cocito D; Schenone A
    J Peripher Nerv Syst; 2020 Dec; 25(4):356-365. PubMed ID: 32808406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy.
    Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R
    Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous immunoglobulins (SCIG) for chronic inflammatory demyelinating polyneuropathy (CIDP): A comprehensive systematic review of clinical studies and meta-analysis.
    Ramzi A; Maya S; Balousha N; Sabet H; Samir A; Roshdy MR; Aljarrah G; Saleh S; Kertam A; Serag I; Shiha MR
    Neurol Sci; 2024 Nov; 45(11):5213-5230. PubMed ID: 38937399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin.
    Ryltoft AK; Al-Zuhairy A; Sindrup SH; Andersen H; Markvardsen LK
    Acta Neurol Scand; 2020 Dec; 142(6):637-640. PubMed ID: 33404110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
    Markvardsen LH; Christiansen I; Jakobsen J
    Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.
    Hartung HP; Mallick R; Bril V; Lewis RA; Sobue G; Lawo JP; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; van Schaik IN;
    Eur J Neurol; 2020 Jan; 27(1):196-203. PubMed ID: 31400231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
    Latov N; Deng C; Dalakas MC; Bril V; Donofrio P; Hanna K; Hartung HP; Hughes RA; Merkies IS; van Doorn PA;
    Arch Neurol; 2010 Jul; 67(7):802-7. PubMed ID: 20457948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs.
    Markvardsen LH; Harbo T
    J Neurol Sci; 2017 Jul; 378():19-25. PubMed ID: 28566163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgPro20, the Polyneuropathy and Treatment with Hizentra
    Berger M; Harbo T; Cornblath DR; Mielke O
    Immunotherapy; 2018 Aug; 10(11):919-933. PubMed ID: 29764262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.